Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | WNT3 | P56703 | 2/20 | 0.43 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2695856 | 0.86 | NR1H2 (0.46) | NR1H2NPC1NPSR1LMNAMEN1 | |
| SCHEMBL1922847 | 0.86 | NR1H2 (0.46) | NR1H2NPC1NPSR1LMNAMEN1 | |
| SCHEMBL25594973 | 0.85 | LMNA (0.48) | NR1H2NPC1NPSR1LMNAMAPT | |
| SCHEMBL28176885 | 0.83 | SLC9A1 (0.44) | NR1H2 | |
| SCHEMBL15553805 | 0.81 | SLC9A1 (0.50) | NR1H2MAPT | |
| SCHEMBL13628052 | 0.80 | NR1H2 (0.45) | NR1H2NPC1NPSR1LMNAMEN1 | |
| SCHEMBL17041234 | 0.79 | RIPK1 (0.50) | NPC1NPSR1LMNAMAPTUCHL1 | |
| SCHEMBL28529044 | 0.79 | NPC1 (0.46) | WNT3SFRP1NPC1NPSR1LMNA | |
| SCHEMBL21198773 | 0.79 | RIPK1 (0.53) | NR1H2NPC1NPSR1LMNAMAPT | |
| SCHEMBL21207072 | 0.79 | RIPK1 (0.53) | NR1H2NPC1NPSR1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | SCHRÖDINGER, INC. | 2023-06-01 | — | — | US | disclosed |
| WO-2023086319-A1 | 6-HE TERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | NR1H2 4625/4885WNT3 1198/4885SFRP1 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.